Table 5.

Estimates for Δ₂ and ${\mathrm{\Delta }}_2^{\prime }$ with different stage-2 treatments as references

Target regimes	Stage-1 treatment	Reference stage-2 treatment	Actual stage-2 treatment
			CVD	KA/VE	TEC	TEE
Δ2
(CVD, TEC)	CVD	TEC	NA	0.03	0	0.24
(KA/VE, TEC)	KA/VE	TEC	0.5	NA	0	0.55
(TEC, CVD)	TEC	CVD	0	0.175	NA	0.25
(TEE, TEC)	TEE	TEC	0.125	0.125	0	NA
${\mathrm{\Delta }}_2^{\prime }$
(CVD, KA/VE)	CVD	KA/VE	NA	0	0–0.03	0.24–0.03
(KA/VE, CVD)	KA/VE	CVD	0	NA	0–0.5	0.55–0.5
(TEC, TEE)	TEC	TEE	0–0.25	0.175–0.25	NA	0
(TEE, CVD)	TEE	CVD	0	0.125–0.125	0–0.125	NA
${\mathrm{\Delta }}_2^{\prime }$
(CVD, TEE)	CVD	TEE	NA	0.03–0.24	0–0.24	0
(KA/VE, TEE)	KA/VE	TEE	0.5–0.55	NA	0–0.55	0
(TEC, KA/VE)	TEC	KA/VE	0–0.175	0	NA	0.25–0.175
(TEE, KA/VE)	TEE	KA/VE	0.125–0.125	0	0–0.125	NA